Referral
Subject: Urgent Referral for Evaluation of a Pediatric Patient with Severe Haematological Abnormalities
Dear Colleague,
I am writing to urgently refer a 2-year-old female patient who presented with alarming hematological symptoms that require specialized evaluation. This previously healthy toddler has suddenly developed nasal bleeding and widespread ecchymosis across her chest and lower limbs.
Clinical Background and Laboratory Findings:
- Nasal Bleeding: Sudden onset, currently intermittent.
- Ecchymosis: Extensive bruising noted over the chest and lower limbs.
- Blood Counts:
- Platelets: 3,000/µL (severely reduced)
- Hemoglobin: 5.6 gm/dL (indicative of severe anemia)
- White Blood Cells: 2,000/µL (leukopenia)
The severity of the thrombocytopenia, along with significant anemia and leukopenia, raises concerns for an acute and potentially life-threatening hematological disorder.
Given the acute nature of her symptoms and the critical laboratory findings, she requires comprehensive diagnostic assessment to determine the underlying cause of these hematological abnormalities. The family is understandably very concerned and has been informed about the need for specialized medical evaluation.
Thank you for your prompt attention to this urgent referral. We are looking forward to your expertise in managing and clarifying this complex pediatric case. Please let us know if you require any further details or specific information prior to her evaluation.
Reply
Dear Colleague,
Thank you for your prompt referral of the 2-year-old girl with significant hematological abnormalities. Upon evaluation, there was no noteworthy past medical history, including absent fever, recurrent infections, or admissions, and no bleeding from other sites was reported.
Clinical Examination: The patient is active and well, with stable hemodynamics. She does not display any dysmorphic features. Examination revealed multiple ecchymoses over her lower limbs and trunk. A nasal pack was in place, with no active bleeding noted. There was no evidence of organomegaly or lymphadenopathy.
Recommended Diagnostic Investigations:
- Repeat CBC: Including differentials and peripheral blood smear
- Reticulocyte Count
- Direct Coombs Test
- Serum Assays: LDH, uric acid, electrolytes, and ESR
- Liver and Renal Function Tests
- Virology Screening: Including HIV, Hepatitis, Parvovirus B19, Varicella, CMV, and EBV
Initial Impression:
The findings thus far suggest bone marrow failure. The differential diagnosis includes atypical immune thrombocytopenia and leukemia. A bone marrow aspirate (BMA) may be indicated as part of the next steps in her diagnostic journey.
Investigation Results:
The repeated CBC confirmed pancytopenia with a very low reticulocyte count, and the peripheral blood smear did not show any abnormal cells. Other laboratory tests returned results within normal limits. Given these findings, we proceeded with a bone marrow aspirate and biopsy.
Bone Marrow Findings: The biopsy revealed a hypocellular marrow with empty bony spicules. There was marked reduction in haematopoiesis, with decreased macrophages, lymphoid cells, and plasma cells. Notably, no megakaryocytes were observed. These findings have led to a diagnosis of aplastic anaemia.
Recommendations:
Given the severity of the aplastic anemia and the risks it poses, we have initiated the process for a bone marrow transplantation. This decision comes after careful consideration of her condition and the need for a potentially curative approach.
We appreciate the thorough initial assessment and timely referral which enabled prompt diagnostic and management actions. We will continue to keep you updated on her progress and our treatment efforts.
Discussion
Aplastic anaemia is a rare, severe disorder defined by the combination of pancytopenia—reduced counts of platelets, red blood cells, and white blood cells—and a markedly hypocellular bone marrow. This condition involves the significant reduction or loss of hematopoietic stem cells and is distinct in that it does not typically involve infiltrative diseases of the bone marrow.
Pathophysiology and Aetiologies: The primary pathophysiological feature of aplastic anaemia involves damage to or loss of pluripotent hematopoietic stem cells. Several constitutional or inherited forms of the disease are recognized in pediatric populations, including Fanconi anaemia, dyskeratosis congenita, Schwachman-Diamond syndrome, and congenital amegakaryocytic thrombocytopenia. These genetic disorders frequently present with unique syndromic features and are diagnosed based on genetic testing alongside bone marrow analysis.
Acquired aplastic anemia has multiple potential causes:
- Idiopathic: The majority of cases remain idiopathic, with no identifiable cause even after thorough investigation.
- Infectious agents: Viral infections like EBV, HIV, hepatitis viruses, and parvovirus have been implicated.
- Toxic exposure: Chemicals such as benzene and certain drugs, as well as radiation, are known risk factors.
- Autoimmune conditions and other medical conditions: These include eosinophilic fasciitis, anorexia, severe nutritional deficiencies (notably vitamin B12 and folate), and conditions like paroxysmal nocturnal haemoglobinuria (PNH) and myelodysplastic syndromes (MDS).
A diagnosis of aplastic anemia is suggested by the presence of pancytopenia with absolute reticulocytopenia suggestive of bone marrow failure. The red blood cells usually are normocytic but occasionally may be macrocytic (mean cell volume >100). Diagnosis of aplastic anaemia is established by bone marrow aspiration and biopsy.
Diagnostic Approach: A bone marrow biopsy is essential for diagnosis, providing a clear assessment of marrow cellularity. Aplastic anaemia typically shows a hypocellular marrow without the infiltration seen in leukemic or fibrotic processes. Technical issues such as dilution with peripheral blood during aspiration can affect the interpretation, thus necessitating both aspirate and biopsy samples.
Prognosis and Treatment: The prognosis in aplastic anaemia largely depends on the severity of pancytopenia. Historically, untreated severe aplastic anaemia has been associated with high mortality rates, with about 70% of patients with severe forms dying within one year without treatment. Treatment strategies include:
- Hematopoietic Stem Cell Transplantation (HSCT): For patients, especially younger ones, with a matched sibling donor, HSCT remains the treatment of choice.
- Immunosuppressive Therapy (IST): Antithymocyte globulin (ATG) combined with cyclosporin A (CSA) is the mainstay of treatment when a suitable donor is not available. This therapy shows a 60-80% initial response rate and a 5-year survival rate of approximately 75%, although long-term event-free survival is considerably lower.
- Supportive Care: Includes transfusions and management of infections.
Recent advances have continued to refine the approach to immunosuppressive therapy and the indications for HSCT. Current research is focusing on understanding the genetic and molecular basis of aplastic anaemia to develop more targeted therapies that could improve outcomes further. Additionally, newer agents such as eltrombopag, a thrombopoietin receptor agonist, have shown promise in increasing blood counts in combination with standard IST, potentially enhancing response rates and survival in refractory cases.
Given the critical nature of timely and appropriate treatment, continuous monitoring and adaptive treatment strategies are essential for managing patients with aplastic anaemia, aiming to improve quality of life and long-term outcomes.
Fanconi Anaemia
Fanconi anaemia is a genetically and phenotypically diverse disorder characterized by congenital anomalies, progressive bone marrow failure, and a heightened risk of hematologic malignancies and solid tumors. Between 60-75% of patients exhibit multiple congenital anomalies, including short stature, abnormal skin pigmentation, and malformations of the thumbs, potentially with dysplastic or absent radii. Additional anomalies can involve microphthalmos, as well as cardiac, renal, gastrointestinal, and auditory malformations.
Haematologically, Fanconi anaemia is marked by a high incidence of bone marrow failure manifesting as thrombocytopenia, leukopenia, or aplastic anaemia, typically developing by adulthood. The risk of hematologic malignancies, particularly myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), is significantly increased, alongside an increased propensity for solid tumors such as squamous cell carcinomas of the head and neck, female genital tract cancers, and liver tumors. This condition is linked to increased chromosomal breakage and abnormal sister chromatid exchange, notably in response to clastogenic agents like diepoxybutane or mitomycin C. Fanconi anaemia follows an autosomal recessive inheritance pattern, with fifteen known causative genes; only FANCB, which is X-linked recessive, deviates from this pattern.
Chromosomal abnormalities in Fanconi anaemia may resemble those seen in non-Fanconi MDS and secondary AML (e.g., -7/7q-, RUNX1 abnormalities), but some are uniquely characteristic of Fanconi anaemia (e.g., gains in 1q, 3q).
Dyskeratosis Congenita
Dyskeratosis congenita is traditionally diagnosed by a triad of physical manifestations: dysplastic nails, lacy reticular skin pigmentation on the upper torso, and oral leucoplakia. However, recent findings indicate that not all patients display this triad. Features of the disease also include signs of premature aging, such as early greying of the hair, and a range of hematologic issues stemming from progressive bone marrow failure which may lead to various cytopenia including aplastic anaemia. Malignancy risks are elevated, particularly for MDS, AML, and solid tumors like those affecting the head and neck or genital areas. Pulmonary fibrosis is another severe complication. Dyskeratosis congenita can be inherited in autosomal dominant, autosomal recessive, or X-linked patterns, with six known causative genes.
Shwachman-Diamond Syndrome
Schwachman-Diamond syndrome results from mutations in the SBDS gene, inherited in an autosomal recessive manner. It is primarily characterized by pancreatic exocrine dysfunction leading to malabsorption and growth failure. Haematological involvement includes cytopenia that may affect single or multiple cell lineages. Patients also face increased risks of developing MDS and AML due to underlying bone marrow dysfunction.
Each of these syndromes requires careful clinical management that encompasses both surveillance for and treatment of haematological complications and associated malignancies, as well as supportive care addressing the systemic manifestations of the diseases. Genetic counselling is recommended for affected families to provide information on the nature of these heritable disorders and their potential transmission to offspring.
Check the correct answers.
Question-1:
Correct Answer: D) Congenital amegakaryocytic thrombocytopenia
Explanation: Congenital amegakaryocytic thrombocytopenia is a primary hematological disorder characterized by the absence of megakaryocytes in an otherwise normal bone marrow, leading to severe thrombocytopenia. It is not typically associated with secondary aplastic anemia, which involves a broader failure of bone marrow function across multiple cell lines due to external factors such as autoimmune diseases, infections, or nutritional deficiencies. Eosinophilic fasciitis, Schwachman-Diamond syndrome (an inherited marrow failure syndrome), and severe vitamin B12 deficiency can all contribute to or are associated with secondary aplastic anemia in pediatric populations.
Question-2:
Correct Answer: C) Hematopoietic stem cell transplantation (HSCT)
Explanation: In cases of aplastic anemia where there is refractory response to initial immunosuppressive therapy and an emergence of PNH clone, which indicates a high risk of disease progression and possibly transformation to more severe hematologic conditions, HSCT is often considered the next appropriate step. HSCT offers the potential for a definitive cure by re-establishing normal hematopoiesis through the introduction of healthy donor stem cells. Eltrombopag could be considered to increase counts transiently, particularly in refractory cases, but it does not address the underlying clonal hematological disorder. High-dose corticosteroids and a repeat course of antithymocyte globulin with cyclosporin A are less likely to be effective in cases where there is already a documented failure of response to immunosuppressive therapy and the emergence of a PNH clone, which often indicates an evolving clonal hematologic disease beyond the scope of immunosuppression alone.
References
- Young NS, Bacigalupo A, Marsh JC. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant 2010; 16:S119.
- Guinan EC. Acquired aplastic anemia in childhood. Hematol Oncol Clin North Am 2009; 23:171.
- Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997; 336:1365.
- A disease of premature ageing – The Lancet
Leave a Reply